TLSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. TriSalus Life Sciences's accounts receivables for the quarter that ended in Mar. 2024 was $4.28 Mil.
Accounts receivable can be measured by Days Sales Outstanding. TriSalus Life Sciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 60.44.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. TriSalus Life Sciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.65.
The historical data trend for TriSalus Life Sciences's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Accounts Receivable | 1.36 | 1.56 | 3.55 |
TriSalus Life Sciences Quarterly Data | |||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Receivable | Get a 7-Day Free Trial | 1.59 | 2.09 | 3.05 | 3.55 | 4.28 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
TriSalus Life Sciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 4.277 | / | 6.457 | * | 91 |
= | 60.44 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), TriSalus Life Sciences's accounts receivable are only considered to be worth 75% of book value:
TriSalus Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (3.97 | + | 0.75 * 4.277 | + | 0.5 * 2.913 | - | 52.812 |
- | 0 | - | 0) | / | 26.7583 | ||
= | -1.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of TriSalus Life Sciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Jodi Devlin | officer: President, Therapeutics | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
James Alecxih | officer: President, Device Technology | C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065 |
Bryan F. Cox | officer: Chief Scientific & Manufact. | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Kerry R Hicks | director | C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228 |
George Kelly Martin | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Jennifer Stevens | officer: Chief Regulatory Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Richard Marshak | officer: Sr.VP, Corp. Dev. & Strategy | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Mary T Szela | director, officer: CEO and President | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Anil K. Singhal | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Sean Murphy | director, officer: Chief Financial Officer | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
Arjun Jj Desai | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Steven C Katz | officer: Chief Medical Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Mats Wahlstrom | director, 10 percent owner | 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Equity Ab Frankenius | 10 percent owner | BOX 984, BORAS V7 SE-501 10 |
From GuruFocus
By Business Wire • 08-10-2023
By Business Wire • 11-04-2023
By Business Wire • 11-07-2023
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.